Navigation Links
FDA OKs Expanded Use of Prostate Cancer Drug
Date:12/10/2012

MONDAY, Dec. 10 (HealthDay News) -- The approved use of the drug Zytiga has been expanded to include treatment of men with late-stage, hormone therapy-resistant prostate cancer before they undergo chemotherapy, the U.S. Food and Drug Administration announced Monday.

Zytiga was initially approved in April 2011 for treatment of prostate cancer patients whose disease had progressed after treatment with the chemotherapy drug docetaxel.

The drug decreases production of the male sex hormone testosterone. In prostate cancer, testosterone stimulates prostate tumors to grow. Drugs or surgery are used to reduce testosterone production or to block the hormone's effects.

However, some men have what's called "castration-resistant" or hormone therapy-resistant prostate cancer, which means that prostate cancer cells continue to grow even with low levels of testosterone, the FDA explained in a news release.

The expanded approval is based on a study of 1,088 men with late-stage, hormone therapy-resistant prostate cancer who took either Zytiga (abiraterone acetate) or an inactive placebo in combination with another drug called prednisone.

Median overall survival was just over 35 months for patients who took Zytiga and about 30 months for those who took the placebo, the FDA noted.

The most common side effects among patients taking Zytiga included fatigue, joint discomfort, swelling caused by fluid retention, hot flush, diarrhea, vomiting, cough, high blood pressure, shortness of breath, urinary tract infection and bruising.

This expanded approval of Zytiga was made under the FDA's priority review program, which offers an accelerated six-month review for drugs that may offer major advances in treatment or provide a treatment when no adequate therapy exists.

"Today's approval demonstrates the benefit of further evaluating a drug in an earlier disease setting and provides patients and health care providers the
'/>"/>

Copyright©2012 ScoutNews,LLC.
All rights reserved

Page: 1 2

Related medicine news :

1. Prostate cancer now detectable by imaging-guided biopsy
2. Targeted prostate biopsy has potential to improve diagnosis of prostate cancer
3. The Project for Natural Health Choices Inc. Issues an Advisory for Men to Consume Flavonoids in their Diet to Protect Against Prostate Cancer
4. Targeted Prostate Cancer Biopsies Might Improve Care: Study
5. Longer life expectancy, aging population necessitate new strategies for prostate cancer care
6. Drug shows promise in prostate cancer spread to bone
7. Clinical trial at GHSU Cancer Center targets advanced prostate cancer
8. COUP-TFII sparks prostate cancer progression
9. UAlberta prostate cancer researcher and team developing homing beacon drugs to target cancer cells
10. Prostate Cancer Websites Often Hard to Understand: Study
11. Mayo Clinic gets FDA approval for new imaging agent for recurrent prostate cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... ... August 28, 2015 , ... The Louis W. Sullivan ... innovation to transform quality and efficiency of healthcare delivery worldwide, announced the release ... aggregated before being publicly shared to document progress and inform policy in a ...
(Date:8/28/2015)... ... August 28, 2015 , ... External Counterpulsation, also known as ECP or ... selling External Counterpulsation (EECP or ECP) machines with a full clinic licence to help ... business since 2007 helping people prevent and reverse heart disease through its ...
(Date:8/28/2015)... ... 28, 2015 , ... Super-Sod launched their new website this summer. ... notable change is the responsive web design. Website users will now have an improved ... quote requests for sod, sign-up for the monthly turf-tips email, and find a local ...
(Date:8/28/2015)... ... , ... On October 3, 2015, BethAnn Telford of TeamBT and Maria Parker of ... a shared mission: to beat brain cancer. In one grueling day, they will race ... to the South Rim over 21.1 miles and more than 10,000 feet of elevation change. ...
(Date:8/27/2015)... ... ... Keck Graduate Institute (KGI), School of Pharmacy celebrated its Second Annual White Coat ... them as members of the 2nd class of the KGI School of Pharmacy and ... service and patient care, the White Coat Ceremony is held every year when new ...
Breaking Medicine News(10 mins):Health News:WEDI's The Sullivan Institute for Healthcare Innovation Releases Gaps in Care Survey 2Health News:Buy New External Counterpulsation (EECP or ECP) With Heart Fit Clinic 2Health News:Women Athletes Cross the Grand Canyon to Raise Funds for Brain Cancer Research – October 3rd 2Health News:KGI School of Pharmacy’s 2nd Annual White Coat Ceremony a Success 2Health News:KGI School of Pharmacy’s 2nd Annual White Coat Ceremony a Success 3Health News:KGI School of Pharmacy’s 2nd Annual White Coat Ceremony a Success 4
... chances of recurrence, death higher than among normal-weight patients ... survivors who are moderately or severely obese face tougher ... a new study reveals. , The finding builds on ... risk for developing colon cancer in the first place. ...
... ... and Summarized Demographic Reporting increases value of Intellimed,s Reporting Tool. , ... Phoenix, Ariz. (PRWEB) March 9, 2010 ... new enhancements to it’s popular medical reporting software system Intellimed Intelligent Client (IM-IC)., , ...
... ... ... ... ...
... ... ... ... ...
... papers, reviews, case reports, editorials and letters ... a wide range of related sciences. ... of radiopharmaceuticals, nuclear and molecular imaging analysis, ... and radionuclide therapy. June-Key Chung, MD, ...
... ... one of America,s Top Ophthalmologist , ... (Vocus) March 9, 2010 -- Khanna Institute of LASIK and ... has been selected as one of the America’s Top Ophthalmologist. Ophthalmologists are eye MD’s. ...
Cached Medicine News:Health News:Obese Colon Cancer Survivors Face Poorer Prognosis 2Health News:Obese Colon Cancer Survivors Face Poorer Prognosis 3Health News:Obese Colon Cancer Survivors Face Poorer Prognosis 4Health News:Intellimed's Popular Data Reporting Software IM-IC (Intelligent Client) Receives Latest Update 2Health News:Parrish Medical Center Sees 30 Percent Improvement in Mortality Using Real-Time Clinical Surveillance Solution from Thomson Reuters 2Health News:Parrish Medical Center Sees 30 Percent Improvement in Mortality Using Real-Time Clinical Surveillance Solution from Thomson Reuters 3Health News:Parrish Medical Center Sees 30 Percent Improvement in Mortality Using Real-Time Clinical Surveillance Solution from Thomson Reuters 4Health News:Parrish Medical Center Sees 30 Percent Improvement in Mortality Using Real-Time Clinical Surveillance Solution from Thomson Reuters 5Health News:Aspen Dental Announces Opening of First Practice In Nebraska 2Health News:Aspen Dental Announces Opening of First Practice In Nebraska 3Health News:Aspen Dental Announces Opening of First Practice In Nebraska 4Health News:Aspen Dental Announces Opening of First Practice In Nebraska 5Health News:Aspen Dental Announces Opening of First Practice In Nebraska 6Health News:Aspen Dental Announces Opening of First Practice In Nebraska 7Health News:Rajesh Khanna, MD Selected as One of America's Top Ophthalmologist 2
(Date:8/27/2015)... Aug. 27, 2015  MiMedx Group, Inc. (NASDAQ: ... human amniotic tissue and patent-protected processes to develop ... Wound Care, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic ... corrected the multiple inaccuracies in the press release ... the recent rulings from the Patent Trial and ...
(Date:8/27/2015)... 27, 2015 According to a ... Type (Integrated, Standalone), by Deployment Mode (Web based, On-Premise, ... Healthcare Service Providers), by Component - Global Trends & ... is estimated at $501.1 Million 2014, and is projected ... of 7.6% from 2014 to 2019. ...
(Date:8/27/2015)... , Aug. 27, 2015  Mytrus, a technology and services ... platform for electronic informed consent has received approval for ... Service (NHS). It is the first time e-Consent technology ... England . Mytrus was also ... in a clinical trial by the U.S. Food and ...
Breaking Medicine Technology:MiMedx Corrects Inaccuracies In MTF Press Release Regarding The Recent Rulings From The Patent Trial And Appeal Board 2MiMedx Corrects Inaccuracies In MTF Press Release Regarding The Recent Rulings From The Patent Trial And Appeal Board 3MiMedx Corrects Inaccuracies In MTF Press Release Regarding The Recent Rulings From The Patent Trial And Appeal Board 4Radiology Information Systems Market Worth $722.7 Million by 2019 2Radiology Information Systems Market Worth $722.7 Million by 2019 3Radiology Information Systems Market Worth $722.7 Million by 2019 4Britain's National Health Service Approves The Use Of Mytrus Technology For Electronic Informed Consent In Clinical Trials 2Britain's National Health Service Approves The Use Of Mytrus Technology For Electronic Informed Consent In Clinical Trials 3Britain's National Health Service Approves The Use Of Mytrus Technology For Electronic Informed Consent In Clinical Trials 4Britain's National Health Service Approves The Use Of Mytrus Technology For Electronic Informed Consent In Clinical Trials 5Britain's National Health Service Approves The Use Of Mytrus Technology For Electronic Informed Consent In Clinical Trials 6Britain's National Health Service Approves The Use Of Mytrus Technology For Electronic Informed Consent In Clinical Trials 7
... March 6, 2012 Biospace Lab S.A. ... College London will collaborate on the development of novel ... of the Biospace Lab PhotonIMAGER™ Optima pre-clinical imaging platform. ... Dr Mark Lythgoe, and molecular probes, Dr Martin Pule, ...
... GP Strategies Corporation (NYSE: GPX ), ... sales and technical training, e-Learning solutions, management consulting and ... CFO Sharon Esposito-Mayer will speak at the ROTH Capital ... 3:30 p.m. PT. The conference will be held at ...
Cached Medicine Technology:Biospace Lab and the Centre for Advanced Biomedical Imaging at University College London to Collaborate on Development of Novel Real-Time in Vivo Optical Imaging Technologies 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: